Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking stock
Fuente:
FierceBiotech
Aardvark Therapeutics has seen its share price halve in value after the company paused a phase 3 study of its lead metabolic asset over heart-related data.